8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 30, 2026·SEC
Material company update
Mar 25, 2026·SEC
Recursion Pharmaceuticals, Inc.(RXRX)Earnings, Financials & Key Ratios
RXRX•NASDAQ
$3.43
$1.53B mkt cap·Price updated May 6, 2026
AboutRecursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.Show more
- Revenue$75M+26.9%
- EBITDA-$564M-27.6%
- Net Income-$645M-39.1%
- EPS (Diluted)-1.44+14.8%
- Gross Margin-61.96%-368.0%
- EBITDA Margin-755.79%-0.5%
- Operating Margin-867.87%-6.6%
- Net Margin-863.35%-9.6%
- ROE-59.54%+3.8%
- ROIC-95.83%+10.4%
- Debt/Equity0.07-34.2%
- Interest Coverage-355.30-20.6%
RXRX Key Insights
Recursion Pharmaceuticals, Inc. (RXRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y sales CAGR of 85.4%
- ✓Trading at only 1.4x book value
✗Weaknesses
- ✗Profits declining 49.3% over 5 years
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 18 (bottom 18%)
- ✗Shares diluted 63.2% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RXRX Price & Volume
Recursion Pharmaceuticals, Inc. (RXRX) stock price & volume — 10-year historical chart
Loading chart...
RXRX Growth Metrics
Recursion Pharmaceuticals, Inc. (RXRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years85.36%
3 Years23.46%
TTM10.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM2.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM32.2%
Return on Capital
10 Years-51.48%
5 Years-49.74%
3 Years-54.32%
Last Year-50.1%
RXRX Recent Earnings
Recursion Pharmaceuticals, Inc. (RXRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 6, 2026EPS
$0.22
Est $0.30
+26.7%
Revenue
$6M
Est $16M
-60.1%
Q1 2026
Feb 25, 2026EPS
$0.21
Est $0.28
+25.0%
Revenue
$35M
Est $25M
+44.0%
Q4 2025
Nov 5, 2025EPS
$0.36
Est $0.38
+5.3%
Revenue
$5M
Est $25M
-78.9%
Q3 2025
Aug 5, 2025EPS
$0.41
Est $0.35
-17.1%
Revenue
$19M
Est $20M
-4.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.22vs $0.30+26.7% | $6Mvs $16M-60.1% |
| Q1 2026 | Feb 25, 2026 | $0.21vs $0.28+25.0% | $35Mvs $25M+44.0% |
| Q4 2025 | Nov 5, 2025 | $0.36vs $0.38+5.3% | $5Mvs $25M-78.9% |
| Q3 2025 | Aug 5, 2025 | $0.41vs $0.35-17.1% | $19Mvs $20M-4.1% |
Based on last 12 quarters of dataView full earnings history →
RXRX Peer Comparison
Recursion Pharmaceuticals, Inc. (RXRX) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SDGR | 969.87M | 12.98 | -9.21 | 23.29% | -40.6% | -30.85% | 0.30 | |
 ABCL | 1.52B | 5.04 | -10.29 | 160.56% | -194.89% | -15.14% | 0.14 | |
 RLAY | 2.44B | 12.92 | -8.02 | 53.44% | -25.54% | -43.94% | 0.06 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 PRTA | 601.85M | 11.18 | -2.47 | -92.84% | -25.21% | -73% | 0.05 |
Compare RXRX vs Peers
Recursion Pharmaceuticals, Inc. (RXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RXRX Income Statement
Recursion Pharmaceuticals, Inc. (RXRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.71M | 3.41M | 10M | 39.68M | 43.88M | 58.84M | 74.68M | 66.29M |
| Revenue Growth % | - | 99.47% | 193% | 296.81% | 10.57% | 34.1% | 26.92% | 10.96% |
| Cost of Goods Sold | 45.81M | 0 | 0 | 48.27M | 42.59M | 45.24M | 120.95M | 89.12M |
| COGS % of Revenue | 2677.32% | - | - | 121.66% | 97.06% | 76.88% | 161.96% | - |
| Gross Profit | -44.1M▲ 0% | 3.41M▲ 107.7% | 10M▲ 193.0% | -8.59M▼ 185.9% | 1.29M▲ 115.0% | 13.6M▲ 955.2% | -46.27M▼ 440.2% | -22.83M▲ 0% |
| Gross Margin % | -2577.32% | 100% | 100% | -21.66% | 2.94% | 23.12% | -61.96% | -34.44% |
| Gross Profit Growth % | - | 107.74% | 193% | -185.94% | 115% | 955.16% | -440.22% | - |
| Operating Expenses | 64.15M | 88.03M | 192.78M | 237.13M | 351.35M | 492.61M | 601.86M | 562.44M |
| OpEx % of Revenue | 3749.39% | 2579.2% | 1927.75% | 597.6% | 800.78% | 837.21% | 805.91% | - |
| Selling, General & Admin | 18.95M | 25.26M | 57.68M | 81.6M | 110.82M | 178.18M | 176.59M | 156.53M |
| SG&A % of Revenue | 1107.6% | 740.05% | 576.82% | 205.64% | 252.58% | 302.83% | 236.46% | - |
| Research & Development | 45.81M | 63.32M | 135.27M | 155.7M | 241.23M | 314.42M | 425.27M | 420.93M |
| R&D % of Revenue | 2677.32% | 1855.23% | 1352.71% | 392.37% | 549.79% | 534.38% | 569.45% | - |
| Other Operating Expenses | -608K | -549K | -178K | -162K | -699K | 0 | 0 | -1.12M |
| Operating Income | -62.44M▲ 0% | -84.61M▼ 35.5% | -182.78M▼ 116.0% | -245.73M▼ 34.4% | -350.06M▼ 42.5% | -479M▼ 36.8% | -648.13M▼ 35.3% | -585.27M▲ 0% |
| Operating Margin % | -3649.39% | -2479.2% | -1827.75% | -619.26% | -797.84% | -814.09% | -867.87% | -882.92% |
| Operating Income Growth % | - | -35.51% | -116.01% | -34.44% | -42.46% | -36.83% | -35.31% | - |
| EBITDA | -58.9M | -80.67M | -174.37M | -233.97M | -325.66M | -442.51M | -564.43M | -520.9M |
| EBITDA Margin % | -3442.31% | -2363.67% | -1743.7% | -589.63% | -742.22% | -752.07% | -755.79% | -785.81% |
| EBITDA Growth % | - | -36.97% | -116.15% | -34.18% | -39.19% | -35.88% | -27.55% | 0.89% |
| D&A (Non-Cash Add-back) | 3.54M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M | 83.7M | 64.37M |
| EBIT | -61.88M | -85.65M | -183.53M | -239.42M | -332.03M | -463.22M | -643.09M | -441.77M |
| Net Interest Income | 1.11M | -1.02M | -2.88M | 6.2M | 19.02M | 14.19M | 20.98M | 15.92M |
| Interest Income | 1.74M | 336K | 73K | 6.25M | 19.12M | 15.76M | 22.79M | 17.23M |
| Interest Expense | 635K | 1.36M | 2.95M | 55K | 97K | 1.57M | 1.81M | 1.31M |
| Other Income/Expense | 562K | -2.39M | -3.7M | 6.25M | 17.93M | 14.22M | 3.24M | 20.91M |
| Pretax Income | -61.88M▲ 0% | -87.01M▼ 40.6% | -186.48M▼ 114.3% | -239.48M▼ 28.4% | -332.13M▼ 38.7% | -464.79M▼ 39.9% | -644.89M▼ 38.8% | -564.36M▲ 0% |
| Pretax Margin % | -3616.54% | -2549.25% | -1864.79% | -603.5% | -756.97% | -789.93% | -863.53% | -851.37% |
| Income Tax | 0 | 0 | 0 | 0 | -4.06M | -1.13M | -136K | -4.58M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 1.22% | 0.24% | 0.02% | 0.81% |
| Net Income | -62.52M▲ 0% | -87.01M▼ 39.2% | -186.48M▼ 114.3% | -239.48M▼ 28.4% | -328.07M▼ 37.0% | -463.66M▼ 41.3% | -644.76M▼ 39.1% | -559.78M▲ 0% |
| Net Margin % | -3654.3% | -2549.25% | -1864.79% | -603.5% | -747.71% | -788.02% | -863.35% | -844.46% |
| Net Income Growth % | - | -39.15% | -114.33% | -28.42% | -36.99% | -41.33% | -39.06% | 2.58% |
| Net Income (Continuing) | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M | -559.78M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.37▲ 0% | -0.52▼ 40.6% | -1.05▼ 100.1% | -1.36▼ 29.5% | -1.58▼ 16.2% | -1.69▼ 7.0% | -1.44▲ 14.8% | -1.06▲ 0% |
| EPS Growth % | - | -40.62% | -100.08% | -29.52% | -16.18% | -6.96% | 14.79% | 32.2% |
| EPS (Basic) | -0.37 | -0.52 | -1.05 | -1.36 | -1.58 | -1.69 | -1.44 | - |
| Diluted Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M | 529.3M |
| Basic Shares Outstanding | 165.79M | 165.79M | 170.27M | 175.54M | 207.85M | 274.21M | 447.45M | 529.3M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RXRX Balance Sheet
Recursion Pharmaceuticals, Inc. (RXRX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 76.4M | 266.44M | 534.72M | 569.81M | 438.14M | 714.27M | 812.85M | 709.56M |
| Cash & Short-Term Investments | 69.88M | 262.13M | 516.56M | 549.91M | 391.56M | 594.35M | 743.29M | 654.47M |
| Cash Only | 69.88M | 262.13M | 285.12M | 549.91M | 391.56M | 594.35M | 743.29M | 654.47M |
| Short-Term Investments | 0 | 0 | 231.45M | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 151K | 156K | 9.09M | 2.75M | 3.09M | 49.17M | 24.65M | 13.59M |
| Days Sales Outstanding | 32.21 | 16.68 | 331.79 | 25.32 | 25.74 | 304.99 | 120.47 | 112.53 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 6.36M | 4.16M | 9.07M | 17.15M | 43.48M | 70.75M | 44.9M | 41.5M |
| Total Non-Current Assets | 25.03M | 32.15M | 75.63M | 131.47M | 215.56M | 734.33M | 661.28M | 629.97M |
| Property, Plant & Equipment | 24.37M | 25.97M | 64.72M | 121.45M | 120.17M | 233.21M | 169.48M | 157.32M |
| Fixed Asset Turnover | 0.07x | 0.13x | 0.15x | 0.33x | 0.37x | 0.25x | 0.44x | 0.38x |
| Goodwill | 0 | 801K | 801K | 801K | 52.06M | 148.87M | 162.16M | 160.17M |
| Intangible Assets | 0 | 1.69M | 1.39M | 1.31M | 36.44M | 335.86M | 309.9M | 294.07M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 5.63M | 0 | 5.63M |
| Other Non-Current Assets | 663K | 3.69M | 8.72M | 7.92M | 6.89M | 8.82M | 18.79M | 64.48M |
| Total Assets | 101.43M▲ 0% | 298.58M▲ 194.4% | 610.35M▲ 104.4% | 701.29M▲ 14.9% | 653.7M▼ 6.8% | 1.45B▲ 121.6% | 1.47B▲ 1.8% | 1.34B▲ 0% |
| Asset Turnover | 0.02x | 0.01x | 0.02x | 0.06x | 0.07x | 0.04x | 0.05x | 0.05x |
| Asset Growth % | - | 194.37% | 104.41% | 14.9% | -6.79% | 121.6% | 1.76% | 164.89% |
| Total Current Liabilities | 6.68M | 23.1M | 46.66M | 100.27M | 93.17M | 187.47M | 147.71M | 129.7M |
| Accounts Payable | 1.26M | 1.07M | 2.82M | 4.59M | 3.95M | 21.61M | 18.12M | 20.35M |
| Days Payables Outstanding | 10.05 | - | - | 34.67 | 33.88 | 174.38 | 54.67 | 73.43 |
| Short-Term Debt | 77K | 1.07M | 90K | 97K | 41K | 22.22M | 21.75M | 22.35M |
| Deferred Revenue (Current) | 0 | 10M | 10M | 56.73M | 36.43M | 61.77M | 37.6M | 157.45M |
| Other Current Liabilities | 1.7M | 3.08M | 11.74M | 20.43M | 23.75M | 81.87M | 70.23M | 74.55M |
| Current Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x | 5.50x | 5.50x |
| Quick Ratio | 11.43x | 11.53x | 11.46x | 5.68x | 4.70x | 3.81x | 5.50x | 5.50x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | 39.11 |
| Total Non-Current Liabilities | 219.01M | 481.77M | 20.75M | 115.22M | 97.09M | 226.34M | 195.56M | 185.05M |
| Long-Term Debt | 12.42M | 11.41M | 633K | 536K | 1.1M | 19.02M | 56.21M | 50.02M |
| Capital Lease Obligations | 3.21M | 2.71M | 9.34M | 44.42M | 43.41M | 67.25M | 0 | 53.4M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.34M | 16.57M | 23.25M | 88.63M |
| Other Non-Current Liabilities | 203.39M | 450.99M | 4.11M | 0 | 0 | 4.73M | 116.09M | 346.64M |
| Total Liabilities | 225.7M | 504.87M | 67.41M | 215.48M | 190.26M | 413.82M | 343.26M | 314.75M |
| Total Debt | 16.17M | 15.66M | 11.48M | 51.01M | 50.67M | 108.49M | 77.97M | 72.38M |
| Net Debt | -53.71M | -246.46M | -273.64M | -498.91M | -340.89M | -485.86M | -665.33M | -582.1M |
| Debt / Equity | - | - | 0.02x | 0.10x | 0.11x | 0.10x | 0.07x | 0.07x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.14x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 1.12x |
| Interest Coverage | -97.45x | -62.98x | -62.17x | -4353.11x | -3423.00x | -294.67x | -355.30x | -336.46x |
| Total Equity | -124.27M▲ 0% | -206.29M▼ 66.0% | 542.94M▲ 363.2% | 485.81M▼ 10.5% | 463.44M▼ 4.6% | 1.03B▲ 123.3% | 1.13B▲ 9.3% | 1.02B▲ 0% |
| Equity Growth % | - | -66.01% | 363.19% | -10.52% | -4.6% | 123.28% | 9.29% | 175.86% |
| Book Value per Share | -0.75 | -1.24 | 3.19 | 2.77 | 2.23 | 3.77 | 2.53 | 1.94 |
| Total Shareholders' Equity | -124.27M | -206.29M | 542.94M | 485.81M | 463.44M | 1.03B | 1.13B | 1.02B |
| Common Stock | 0 | 0 | 2K | 2K | 2K | 4K | 5K | 5K |
| Retained Earnings | -126.59M | -213.6M | -400.08M | -639.56M | -967.62M | -1.43B | -2.08B | -2.19B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -126K | 0 | 0 | -7.64M | 36.72M | 26.66M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RXRX Cash Flow Statement
Recursion Pharmaceuticals, Inc. (RXRX) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -57.04M | -45.4M | -158.61M | -83.52M | -287.78M | -359.17M | -371.81M | -371.81M |
| Operating CF Margin % | -3333.84% | -1330.18% | -1586.14% | -210.49% | -655.89% | -610.44% | -497.86% | - |
| Operating CF Growth % | - | 20.41% | -249.38% | 47.34% | -244.55% | -24.81% | -3.52% | 7.52% |
| Net Income | -61.88M | -87.01M | -186.48M | -239.48M | -328.07M | -463.66M | -644.76M | -559.78M |
| Depreciation & Amortization | 2.49M | 3.94M | 8.4M | 11.76M | 24.4M | 36.49M | 83.7M | 84.04M |
| Stock-Based Compensation | 1.39M | 4.29M | 14.84M | 27.91M | 53.5M | 81.69M | 111.22M | 97.38M |
| Deferred Taxes | 0 | 0 | 827K | 0 | 0 | 0 | 0 | -4.6M |
| Other Non-Cash Items | 555K | 2.54M | 4.1M | 11.37M | 12.64M | 24.31M | 64.34M | 42.46M |
| Working Capital Changes | 408K | 30.83M | -306K | 104.92M | -50.26M | -38M | 13.69M | 19.54M |
| Change in Receivables | 605K | -1.12M | 114K | -2K | 0 | -6.07M | 32.94M | 28.1M |
| Change in Inventory | 0 | 0 | 7.83M | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -340K | -185K | 1.75M | 1.77M | -987K | 6.43M | -2.62M | -4.24M |
| Cash from Investing | -3.91M | -8.74M | -271.74M | 193.25M | -10.23M | 260.06M | -16.87M | -9.94M |
| Capital Expenditures | -3.91M | -5.83M | -39.8M | -37.06M | -11.96M | -13.7M | -6.47M | -4.89M |
| CapEx % of Revenue | 228.52% | 170.85% | 397.98% | 93.39% | 27.25% | 23.28% | 8.66% | - |
| Acquisitions | 0 | -2.6M | 231.95M | 0 | 1.84M | 277.1M | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -309K | -231.95M | -300K | -597K | -3.35M | -6.6M | -2.24M |
| Cash from Financing | 120.41M | 246.13M | 458.54M | 154.34M | 140.13M | 304.12M | 521.53M | 477.54M |
| Debt Issued (Net) | 705K | 6.32M | -12.8M | -90K | -766K | -4.44M | -8.43M | -6.38M |
| Equity Issued (Net) | 119.92M | 239.13M | 462.9M | 143.71M | 128.09M | 300.42M | 532.96M | 491.38M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -210K | 681K | 8.44M | 10.72M | 12.81M | 8.14M | -3M | -7.46M |
| Net Change in Cash | 59.46M▲ 0% | 192M▲ 222.9% | 28.18M▼ 85.3% | 263.76M▲ 835.9% | -157.69M▼ 159.8% | 201.6M▲ 227.8% | 150.9M▼ 25.1% | 156.02M▲ 0% |
| Free Cash Flow | -60.95M▲ 0% | -52.13M▲ 14.5% | -198.41M▼ 280.6% | -120.88M▲ 39.1% | -300.33M▼ 148.4% | -372.87M▼ 24.2% | -378.28M▼ 1.5% | -325.85M▲ 0% |
| FCF Margin % | -3562.36% | -1527.51% | -1984.12% | -304.64% | -684.5% | -633.71% | -506.52% | -491.56% |
| FCF Growth % | - | 14.47% | -280.58% | 39.07% | -148.45% | -24.15% | -1.45% | 18.75% |
| FCF per Share | -0.37 | -0.31 | -1.17 | -0.69 | -1.44 | -1.36 | -0.85 | -0.85 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x | 0.58x | 0.58x |
| Interest Paid | 485K | 989K | 0 | 55K | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RXRX Key Ratios
Recursion Pharmaceuticals, Inc. (RXRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -110.79% | -46.56% | -69.12% | -61.9% | -59.54% | -54.32% |
| Return on Invested Capital (ROIC) | - | - | -143.87% | -479.79% | -107.01% | -95.83% | -95.83% |
| Gross Margin | 100% | 100% | -21.66% | 2.94% | 23.12% | -61.96% | -34.44% |
| Net Margin | -2549.25% | -1864.79% | -603.5% | -747.71% | -788.02% | -863.35% | -844.46% |
| Debt / Equity | - | 0.02x | 0.10x | 0.11x | 0.10x | 0.07x | 0.07x |
| Interest Coverage | -62.98x | -62.17x | -4353.11x | -3423.00x | -294.67x | -355.30x | -336.46x |
| FCF Conversion | 0.52x | 0.85x | 0.35x | 0.88x | 0.77x | 0.58x | 0.58x |
| Revenue Growth | 99.47% | 193% | 296.81% | 10.57% | 34.1% | 26.92% | 10.96% |
RXRX SEC Filings & Documents
Recursion Pharmaceuticals, Inc. (RXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
RXRX Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (RXRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Recursion Pharmaceuticals, Inc. (RXRX) reported $66.3M in revenue for fiscal year 2025. This represents a 3774% increase from $1.7M in 2019.
Recursion Pharmaceuticals, Inc. (RXRX) grew revenue by 26.9% over the past year. This is strong growth.
Recursion Pharmaceuticals, Inc. (RXRX) reported a net loss of $559.8M for fiscal year 2025.
Dividend & Returns
Recursion Pharmaceuticals, Inc. (RXRX) has a return on equity (ROE) of -59.5%. Negative ROE indicates the company is unprofitable.
Recursion Pharmaceuticals, Inc. (RXRX) had negative free cash flow of $325.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More RXRX
Recursion Pharmaceuticals, Inc. (RXRX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates